Major
acetylsalicylic acid × spironolactone
Antiplatelet agents (low dose) / NSAIDs (analgesic dose)×Potassium-sparing diuretics (mineralocorticoid receptor antagonists)
Mechanism
Aspirin's NSAID effect reduces prostaglandin-dependent renal perfusion and blunts the diuretic and natriuretic action of spironolactone. Antiplatelet doses of 75–100 mg barely affect renal prostaglandin synthesis. Analgesic and antipyretic doses of 500–1000 mg and above suppress renal prostaglandin synthesis systemically – similar to ibuprofen and naproxen. HF patients may decompensate. Additionally, additive GI bleeding risk (synergistic gastrotoxicity from COX inhibition plus the erosive action of aspirin).
Management
In HF, low antiplatelet aspirin doses of 75–100 mg are acceptable – clinically meaningful diuretic blunting is unlikely. Analgesic and antipyretic doses of 500–1000 mg and above are contraindicated in HF NYHA II–IV and/or eGFR below 60 mL/min (AHA 2016 and ESC HF 2024 guidelines) – replace with paracetamol. For worsening edema or a 2 kg or greater weight gain over 3 days, check creatinine and seek medical review.
Sources
- AHA: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association (2016)— Circulation 2016;134(6):e32–e69
- ESC: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021)— Eur Heart J 2021;42(36):3599–3726
- ESC: 2023 Focused Update of the 2021 ESC Guidelines for the treatment of heart failure (2023)— Eur Heart J 2023;44(37):3627–3639
- FDA: FDA Drug Safety Communication: FDA strengthens warning that non-aspirin NSAIDs can cause heart attacks or strokes (2015)— FDA Drug Safety Communication, July 9, 2015